EDGAR·FLOW

Aptevo Therapeutics Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Aptevo reported Q3 2026 results showing mipletamig achieved 79% CR/CRi remission rate in 14 evaluable TP53-mutated AML patients (vs. 41% historical benchmark), with 10 of 47 patients advancing to stem cell transplantation. In August 2026, the company raised $4.5M gross ($4.1M net) through warrant exercises (254,922 shares at $4.03) and private placement (861,708 shares/pre-funded warrants at $4.03), plus new warrants covering 5.6M shares at $4.03. Cash position declined to $8.3M (Sept 30) from $9.8M (June 30); Q3 net loss was $6.5M.
Why this rating

Clinical efficacy data materially strengthens lead candidate; $4.5M capital raise is 46% of market cap, extending runway. Event is significant relative to $9.8M company size, though cash burn remains substantial risk.

Tradability signal
NO TRADE

No trade: only ~$26k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.63 ▲ 4.08%
at our read · unknown
$0.61
+10 min · unknown
$0.60 ▼ 1.52%
+30 min · unknown
$0.60 ▼ 0.91%
+1 hr · unknown
$0.56 ▼ 7.47%
+4 hrs · unknown
$0.55 ▼ 9.78%

The stock had already moved -3.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ APVO · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.